Literature DB >> 20336408

The effect of needle number on the quality of high-dose-rate prostate brachytherapy implants.

Georgina Fröhlich1, Péter Agoston, József Lövey, Csaba Polgár, Tibor Major.   

Abstract

The aim of this study is to evaluate the effect of the number of needles on the quality of dose distributions in high-dose-rate (HDR) prostate implants regarding target coverage, dose homogeneity and dose to organs at risk. Treatment plans of 174 implants were evaluated using cumulative dose-volume histograms. The plans were divided into three groups according to the number of implanted needles: <15: LNG (low number group), 15-17: MNG (medium number group) and >17: HNG (high number group). Treatment planning was based on transrectal ultrasound imaging. Dose-volume parameters for target (V90, V100, V150, V200, D90, D(min)) and quality indices (DNR, DHI, CI, COIN) were calculated. Maximal dose in reference points and high dose volumes were determined for rectum and urethra. Nonparametric analysis of variance and correlation was used with regard to needle numbers. Between the groups differences were found only in the following parameters: V(p) was larger when more needles were used with the values of 22.8 cm(3), 28.0 cm(3) and 30.9 cm(3) for the three groups, and more needles were used when the central cross-section of the prostate was larger. V200 in MNG was lower than in LNG (12%, 14%). Dose to rectum was higher in MNG than in LNG (D(2): 51%, 47%). Doses to the urethra were higher in HNG than in MNG (D1: 142%, 137%, and D(0.1): 128%, 125%). There was no significant difference in other parameters. Different number of needles results significant differences in treatment plans. However, the optimal needle number depends on not only the size of the prostate, but also the individual anatomy of the patient. Based on our results, in most cases the use of 15-17 needles seems to provide a dosimetrically acceptable treatment plan in HDR prostate implants.

Entities:  

Mesh:

Year:  2010        PMID: 20336408     DOI: 10.1007/s12253-010-9252-z

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  31 in total

Review 1.  The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis.

Authors:  S Nag; W Bice; K DeWyngaert; B Prestidge; R Stock; Y Yu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-01-01       Impact factor: 7.038

2.  Analysis of interaction between number of implant catheters and dose-volume histograms in prostate high- dose-rate brachytherapy using a computer model.

Authors:  Claire Charra-Brunaud; I-Chow J Hsu; Vivian Weinberg; Jean Pouliot
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-06-01       Impact factor: 7.038

3.  Evaluation of anatomy-based dwell position and inverse optimization in high-dose-rate brachytherapy of prostate cancer: a dosimetric comparison to a conventional cylindrical dwell position, geometric optimization, and dose-point optimization.

Authors:  Yasuo Yoshioka; Tetsuo Nishimura; Minoru Kamata; Hideyuki Harada; Kenta Kanazawa; Hiroshi Fuji; Shigeyuki Murayama
Journal:  Radiother Oncol       Date:  2005-06       Impact factor: 6.280

4.  Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate.

Authors:  Jinka R Sathya; Ian R Davis; Jim A Julian; Qing Guo; Dean Daya; Ian S Dayes; Himu R Lukka; Mark Levine
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

Review 5.  The emerging role of high-dose-rate brachytherapy for prostate cancer.

Authors:  G C Morton
Journal:  Clin Oncol (R Coll Radiol)       Date:  2005-06       Impact factor: 4.126

6.  Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.

Authors:  Michael Pinkawa; Karin Fischedick; Peter Treusacher; Branka Asadpour; Bernd Gagel; Marc D Piroth; Holger Borchers; Gerhard Jakse; Michael J Eble
Journal:  Radiother Oncol       Date:  2005-11-04       Impact factor: 6.280

7.  GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer.

Authors:  György Kovács; Richard Pötter; Tillmann Loch; Josef Hammer; Inger-Karine Kolkman-Deurloo; Jean J M C H de la Rosette; Hagen Bertermann
Journal:  Radiother Oncol       Date:  2005-02       Impact factor: 6.280

8.  3D interstitial HDR brachytherapy combined with 3D external beam radiotherapy and androgen deprivation for prostate cancer. Preliminary results.

Authors:  T Martin; S Hey-Koch; G Strassmann; C Kolotas; D Baltas; B Rogge; S Röddiger; H G Vogt; R Heyd; T Dannenberg; R Kurek; U Tunn; N Zamboglou
Journal:  Strahlenther Onkol       Date:  2000-08       Impact factor: 3.621

9.  Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.

Authors:  Tetsuo Akimoto; Kazuto Ito; Jun-ichi Saitoh; Shin-ei Noda; Koichi Harashima; Hideyuki Sakurai; Yuko Nakayama; Takumi Yamamoto; Kazuhiro Suzuki; Takashi Nakano; Hideo Niibe
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-01       Impact factor: 7.038

Review 10.  Radiotherapeutic techniques for prostate cancer, dose escalation and brachytherapy.

Authors:  V S Khoo
Journal:  Clin Oncol (R Coll Radiol)       Date:  2005-10       Impact factor: 4.126

View more
  2 in total

1.  High-dose-rate brachytherapy combined with hypofractionated external beam radiotherapy for men with intermediate or high risk prostate cancer: analysis of short- and medium-term urinary toxicity and biochemical control.

Authors:  Antonio Cassio Assis Pellizzon; Ricardo Cesar Fogaroli; Maria Leticia Gobo Silva; Douglas Guedes Castro; Maria Conte Maia; Ademar Lopes
Journal:  Int J Clin Exp Med       Date:  2010-12-26

2.  Axially rigid steerable needle with compliant active tip control.

Authors:  M de Vries; J Sikorski; S Misra; J J van den Dobbelsteen
Journal:  PLoS One       Date:  2021-12-16       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.